Abstract
Org OD 14 (tibilone) is a synthetic steroid, designed to combine the favourable effects of oestrogens, progestagens and androgens into a single substance for use as hormone replacement therapy (HRT). Given its antiovulatory properties, the ability to control menopausal symptoms and blocking action on progesterone receptors, Org OD 14 was considered as an agent with potential anti-cancer activity while at the same time helping existing menopausal symptoms. In this phase II study, 14 post-menopausal women with advanced or metastatic breast cancer, who had failed on tamoxifen, were treated with Org OD 14. The median duration of treatment was 12 weeks and all patients stopped because of progressive disease with or without toxicity. Vaginal bleeding occurred in four patients, three of whom had recently stopped tamoxifen. One response was seen: an 82-year-old patient had a partial response in an axillary soft tissue mass, improvement in liver function tests and an improvement in her performance status that lasted over 6 months. One patient with progressive disease on Org OD 14 improved on stopping the drug. In view of the vaginal bleeding, Org OD 14 should not be given to patients who have recently stopped tamoxifen.
Full text
PDF


Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dupont W. D., Page D. L. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med. 1991 Jan;151(1):67–72. [PubMed] [Google Scholar]
- Hayward J. L., Carbone P. P., Heusen J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. doi: 10.1038/bjc.1977.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Iveson T. J., Ahern J., Smith I. E. Response to third-line endocrine treatment for advanced breast cancer. Eur J Cancer. 1993;29A(4):572–574. doi: 10.1016/s0959-8049(05)80154-6. [DOI] [PubMed] [Google Scholar]
- Lindsay R., Hart D. M., Purdie D., Ferguson M. M., Clark A. S., Kraszewski A. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med. 1978 Feb;54(2):193–195. doi: 10.1042/cs0540193. [DOI] [PubMed] [Google Scholar]
- Powles T. J., Hickish T., Casey S., O'Brien M. Hormone replacement after breast cancer. Lancet. 1993 Jul 3;342(8862):60–61. doi: 10.1016/0140-6736(93)91931-b. [DOI] [PubMed] [Google Scholar]
- STOLL B. A. FACT AND FALLACY IN THE HORMONAL CONTROL OF BREAST CANCER. Med J Aust. 1964 Jun 27;1:980–982. doi: 10.5694/j.1326-5377.1964.tb127993.x. [DOI] [PubMed] [Google Scholar]
- Sherwin B. B., Gelfand M. M. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol. 1985 Jan 15;151(2):153–160. doi: 10.1016/0002-9378(85)90001-8. [DOI] [PubMed] [Google Scholar]
- Smith I. E., Ford H. T., Gazet J. C., Powles T. J. Premarin in the management of metastatic breast carcinoma in post-menopausal patients. Clin Oncol. 1979 Jun;5(2):159–162. [PubMed] [Google Scholar]
- Tax L., Goorissen E. M., Kicovic P. M. Clinical profile of Org OD 14. Maturitas. 1987;Suppl 1:3–13. doi: 10.1016/0378-5122(87)90038-7. [DOI] [PubMed] [Google Scholar]
- Trévoux R., Dieulangard P., Blum A. Efficacy and safety of Org OD 14 in the treatment of climacteric complaints. Maturitas. 1983 Aug;5(2):89–96. doi: 10.1016/0378-5122(83)90004-x. [DOI] [PubMed] [Google Scholar]
